Volume 53, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In 1995, 24 million travelers from the United States are anticipated to visit developing countries where hepatitis A is endemic. Passive immunization with immune globulin, before exposure or within two weeks following exposure to the hepatitis A virus, protects against clinical disease in < 70–90% of immunized individuals. The duration of protection, measured in months, is relatively short. Active immunization with a single dose of inactivated hepatitis A virus vaccine appears to provide greater protective efficacy and, based on the persistence of vaccine-induced protective antibodies, should provide protection for years. Booster doses given between six and 12 months are likely to provide immunity that may persist for at least a decade. The inactivated hepatitis A vaccine approved for use in the United States has been clinically well-tolerated; mild transient soreness at the injection site is the most frequently reported adverse reaction. Immunization with inactivated hepatitis A vaccine is a safe and effective method for travelers to endemic areas to protect themselves against this infection.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error